The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study

Mahsa Ahadi¹, Afshin Moradi²*, Leila Musavinejad¹, Abolfazl Movafagh³, Arsham Moradi⁴

Abstract

**Background and objectives:** Gastric cancer is known as one of the most common cancers and causes of deaths. Early and proper diagnosis is one of the most important things for treatment response. Therefore, this study aimed to determine the expression of p53, CD44, Ki-67, and HER-2/neu markers in the gastric cancer and its relationship with histopathological indicators. **Methods:** This is a descriptive-analytical study on 60 patients with cancer who underwent gastrectomy surgery in 2011-2016 in Shohadaye Tajrish Hospital. The participants were investigated for p53, CD44, Ki-67, and HER-2/neu markers’ staining plus demographic characteristics, rate of survival, and histopathological features of the tumors. **Results:** The mean age of the participants (44 males and 16 females) was 60.25±12.29 years. The patients’ survival rate was 23.82±1.56 months on average. The tumor size was reported as 6.09±2.61 cm and the major tumor type reported was intestinal type (n=40, 66.7%). The level of expression of Ki-67 and CD44 markers was recorded as 33.75 and 24.50%, and p53 and HER-2/neu immunostains were positive in 25 (41.7%) and 20 (33.3%) patients, respectively. The expression of p53 and CD44 markers had no significant relationship with the demographic characteristics, rate of survival, and histopathological features of the tumor of patients (all p>0.05). The expression of p53 gene was associated with a lower rate of survival (p=0.014), while the expression of HER-2/neu was associated with higher probability of developing intestinal type of stomach adenocarcinoma (p=0.010) and ulcerative macroscopic view (p=0.034). **Conclusion:** This study illustrated that p53 and CD44 markers did not have any diagnostic value in predicting the biological behavior of gastric cancer. In fact, incidence of p53 immunoreactivity was associated with the lower rate of survival, and the expression of HER-2/neu was associated with higher probability of developing the intestinal type of stomach adenocarcinoma and ulcerative macroscopic view.

**Keywords:** p53, CD44, Ki-67, HER-2/neu, gastric cancer

Introduction

Based on the latest statistics of the cancer research center of the country, gastric cancer is the most common cancer among men and the third most common cancer among the Iranian women following breast cancer and colon cancer (Mohagheghi, 2004; Mohagheghi et al., 1998). Nevertheless, there is considerable geographical differences in this classification due to the effect of environmental and genetic factors (Morales, 1997). The main risk factor of distal gastric cancer includes infection with H. pylori and nutritional factors. On the other hand, gastroesophageal reflux disease (GERD) and obesity play a significant role in developing the cancer in the proximal part of the stomach (Correa 1992; Parsonnet et al., 1991; Trédaniel et al., 1997; DeVita et al., 2008).

At the molecular level, stomach tumor originates from several genetic variations, including oncogenes, tumor suppressor genes, and cell cycle regulators. However, their pathogenesis is still unknown. One of the most well-known of these genes is p53 whose role in many cancers, including gastric cancer, has been well established (Smith et al., 2006; Jovanović et al., 2005). It is notable that mutation in p53 is progressive, and patients with the mutated gene have a shorter lifespan compared to the patients, in which this gene has not been mutated (Milner and Watson, 1990). Investigation of the survival of patients across different studies suggested that overexpression of p53 is associated with the histologic type of gastric cancers as well as the prognosis of the disease, and its...
role as a carcinogenic factor in the gastric cancer has been strongly recommended (Shun et al., 1997; Liu et al., 2001). Another gene is HER-2/neu and the gene related to it lies on chromosome 17 and produces a transmembrane glycoprotein, where this glycoprotein functions with a special tyrosine kinase (Kunz et al., 2012). In addition, some studies have associated overexpression of this gene with a worse prognosis, more aggressive behavior, and extensive growth (Al-Moundhri et al., 2005).

Ki-67 identifies a special proliferation antigen. It is expressed by the cells, which are in the terminal stages of G1, S, G2, and M phase, though it is not expressed in the cells in G0. It’s staining is usually nuclear or circump-nuclear. The extent of cellular proliferation, which is investigated through Ki-67 immunoreactivity, has been studied as a prognosis indicator in several malignant neoplasms and results showed its relationship with the size of tumor and its clinical course (Al-Moundhri et al., 2005; Lindboe et al., 2003).

Considering the proof of the key role of mutation of some tumor suppressor genes such as p53 in the incidence of some cancers as well as changes in the incidence of the cell cycle regulator protein and cellular proliferation marker Ki-67 as well as the expression of HER-2/neu and CD44 genes in many cancers, the relationship between their immunohistochemistry, clinical, and pathological indicators of tumors can be determined. Thus, this study aimed to determine the relationship between immunohistochemistry of p53, CD44, Ki-67, and HER-2/neu genes and demographic characteristics as well as pathological findings, alongside the state and site of cancer and prognosis of these patients to identify high-risk patients and determine the therapeutic regime.

Materials and Methods

Methods

This descriptive-analytical and cross-sectional study was conducted across a population with gastric cancer who underwent gastrectomy surgery in Shohahadey Tajrish Hospital in 2011-2016. The studied population was chosen through simple available sampling in a non-probabilistic way. In order to prepare the samples related to stomach carcinoma, 60 patients who underwent gastrectomy in 2011-2016 were extracted by referring to the archive of the pathology ward of the mentioned hospital, out of the list of gastric cancers. Then, by investigating the relevant slides, the best paraffin block with each having the maximum tumor volume was chosen and separated. After cutting the relevant blocks, hematoxylin and Eosin (H and E) staining and staining through immunohistochemistry (IHC) were performed for p53, CD44, Ki-67, and HER-2/neu markers. The results obtained from the staining of the markers through IHC were evaluated with histopathological findings obtained from the file of patients in the archive and staining (H and E), including age, gender, tumor size, site of tumor (cardia, fundus, antrum), macroscopic view ( ulcerative, fungal-shaped, infiltrative), histological degree (G1, G2, and G3), type of tumor according to Loren classification (intestinal, diffuse), T-stage, metastasis to lymph nodes, lymphovascular invasion, and rate of survival.

Immunohistochemistry and its staining assessment

The expression of p53, Ki-67, and HER-2/neu was investigated through immunohistochemistry method. Streptavidin, biotin, peroxidase complex method (labeled Strept - Avidin Biotio/HRP) was implemented on 4-mcm cuts of the tissues cut over paraffin blocks. The used slides were hyalinized for better adhesion of the tissue to the glass slide. After cutting and de-paraffinizing in xylol and dewatering in alcohol, the cuts were incubated in hydrogen peroxide 3% in water for 20 min in order to inhibit the activity of internal peroxidase. Then, for retrieval of antigen, the tissue cuts were placed inside buffer citrate solution (pH=6, 0.01 M) and placed inside in an autoclave at 121°C for 20 min. Next, the cuts were stained using the special antibodies of each marker through the following method: For p53, Monoclonal Mouse Anti-Human p53 Protein Clone DO-7 DAKO (Code N1581) and for Ki-67, Monoclonal Mouse Anti-Human Ki-67 Antigen Clone MIB-1 DAKO (Code N1633) were used. Based on the recommendation of the brochures of each of the kits, the initial incubation time for these primary antibodies was 25 min at room temperature. After washing with TBS, the slides were incubated at room temperature by a layer of Biotinylated Goat Anti- Rabbit/Mouse immunoglobulins (secondary antibodies) in a phosphate buffered saline (PBS) containing stabilizing protein. For each of the above-mentioned markers, an extra cut was stained without applying the primary antibody as negative control. Next, streptavidin conjugated with horseradish peroxidase in buffer solution was added to the cuts (incubation time: 25 min). After washing and adding one drop of substrate-Chromogen with 10 min incubation, the slides were prepared for the last stage, which was cross staining with HandE (DAKO LSAB2 System - HRP).

The scoring criteria were considered as follows for p53, CD44, Ki-67, and HER-2/neu based on the staining intensity and proportion of the nuclear staining. The cutoff value for positivity or negativity of p53, CD44, Ki-67, and HER-2/neu was determined as follows (35):

- p53 staining was considered positive when any amount of tumor cells was stainable.
- Ki-67 staining was considered when >10% of tumoral cells had a medium stainability intensity.
- HER-2/neu staining was considered positive when the tumoral cells had moderate (++) staining intensity or above.
- CD44 staining was considered positive when >50% of the tumoral cells were stainable.

Concerning the ethical principles and confidentiality, information obtained from all samples remained confidential. Moreover, Kolmogorov-Smirnov test was used to examine the distribution normality of the scores. As this test was insignificant, independent t-test was used for comparing two groups, plus Chi-do as well as repeated measures ANOVA. In addition, P-value=0.05 was considered as the minimum value for statistical significance. Finally, all analyses were performed in SPSS 22.
Results

Demographic characteristics of patients and their tumor properties were investigated in this study. Out of the 60 patients studied, 44 were male and 16 were female. The mean age of the patients was 60.25±1.29, and the extent of the patients’ survival was 23.82±1.56 months on average. Table 1 reports other results obtained from this investigation.

Based on the investigations in this study, the intended variables, including the tumor features and information of patients were investigated considering the extent of expression of p53 and HER-2/neu. Table 2 shows the results obtained from the relationship between demographic variables as well as tumor features and the extent of expression of p53 and HER-2/neu. According to the results, the rate of the patients’ survival had a significant relationship with the incidence of p53 (p-value=0.014). This means that the expression of p53 gene was associated with a lower rate of survival in the stomach adenocarcinoma patients. Investigating HER-2/neu, as with p53, in the patients with this marker demonstrated that 75% had an ulcerative tumor, and 50% and 47.5% in negative HER-2/neu patients had ulcerative and infiltrative tumors, respectively. This difference was significant (p=0.034), and the expression of HER-2/neu was associated with ulcerative tumors with a higher probability. Moreover, according to the results, there was a significant relationship between the type of tumor and the expression of HER-2/neu with p=0.010. Based on this finding, it could be stated that the expression of HER-2/neu gene was more likely to be associated with the intestinal type of stomach adenocarcinoma.

The present study investigated demographic characteristics of the patients including age, gender, and rate of survival based on the extent of expression of Ki-67 and CD44 according to stainability. Diagram 1 shows the results. In addition, the tumor characteristics were investigated considering the extent of expression of

| Variables                  | Group       | Mean/Frequency | Stdev/Percentage |
|----------------------------|-------------|----------------|------------------|
| Tumor type                 | Intestinal  | 40             | 66.7             |
|                            | Diffuse     | 10             | 16.7             |
|                            | Mixed       | 3              | 5                |
|                            | Mucinous    | 7              | 11.7             |
| Macroscopic view           | Ulcerative  | 35             | 58.3             |
|                            | Polypoid    | 3              | 5                |
|                            | Infiltrative| 22             | 36.7             |
| Tumor location             | Corpus      | 20             | 33.3             |
|                            | Fundus      | 3              | 5                |
|                            | Antrum      | 20             | 33.3             |
|                            | Cardia      | 12             | 20               |
|                            | Pre-pyloric | 5              | 8.3              |
| Tumor Grade                | Grade 1     | 6              | 10               |
|                            | Grade 2     | 24             | 40               |
|                            | Grade 3     | 30             | 50               |
| Tumor Stage                | T1          | 1              | 1.7              |
|                            | T2          | 10             | 16.7             |
|                            | T3          | 20             | 33.3             |
|                            | T4          | 29             | 48.3             |
| Tumor size (Cm)            | -           | 6.09           | 2.61             |
| Survival rate (months)     | -           | 23.82          | 1.56             |
| Ki-67 expression (%)       | -           | 33.75          | 34.1             |
| CD44 expression (%)        | -           | 24.5           | 32.2             |
| Lymph node involvement     | N0          | 13             | 21.7             |
|                            | N1          | 14             | 23.3             |
|                            | N2          | 15             | 25               |
|                            | N3          | 18             | 30               |
| Lymphovascular invasion    | Lymph+ Vasc+| 28             | 46.7             |
|                            | Lymph- Vasc-| 17             | 28.3             |
|                            | Lymph+ Vasc-| 11             | 18.3             |
|                            | Lymph- Vasc+| 4              | 6.7              |
| P53 expression             | Positive    | 25             | 41.7             |
|                            | Negative    | 34             | 56.7             |
| HER-2 / neu expression     | Positive    | 20             | 33.3             |
|                            | Negative    | 40             | 66.7             |

Figure 1. Evaluation of Age, Survival Rate and Tumor Size with Respect to Expression Levels of P53 and HER-2/neu
Ki-67 and CD44. Table 3 presents the results obtained from the relationship between tumor characteristics and the extent of expression of Ki-67 and CD44. According to the results mentioned in Diagram 1 and Table 3, no significant relationship was found between demographic characteristics and tumor features considering the extent of expression of Ki-67 and CD44.

**Discussion**

This study was a descriptive-analytical study in which the stomach file of 60 patients with cancer undergoing gastrectomy in Tajrish Hospital in 2011-2016 was extracted and investigated for staining p53, Ki-67, CD44, and HER-2/neu, along with the demographic characteristics of patients, rate of survival, and histopathological features of tumors. Based on the findings of the study, p53 and CD44 markers do not have any diagnostic value in predicting the biological behavior of gastric cancer. Moreover, incidence of p53 mutation expression was related to the lower rate of survival, and the expression of HER-2/neu was related to higher probability of developing the intestinal type of stomach adenocarcinoma and ulcerative macroscopic view (Shafigh et al., 2007).

In the study by Staib et al., (2005), it was found that chronic inflammation can initiate carcinogenesis and cause progress of tumor and metastasis. Indeed, inflammatory response is a complicated biological network, and p53 plays a key role in its expression. Therefore, patients with p53 mutations have a worse prognosis compared to the patients without this mutation. The study conducted by Pinto-de-Sousa et al., (2004) on 163 patients with cancer showed that mutation in p53 gene was associated with the vascular invasion, lymphatic metastasis, and higher five-year survival, and the expression of this gene was associated with more aggressive characteristics in the stomach carcinoma. The present study also showed that the patients with a mutation in p53 had a significantly lower rate of survival (around 11 months). In this population of patients, larger
The expression of \( p53 \), CD44, Ki-67, and HER-2/neu markers in gastric cancer

Percentages of lymphatic metastasis and lymphovascular invasion were observed in comparison with the patients without it (though not statistically significant). Moreover, Joypaul et al., (1994) investigated a sample of 260 patients with stomach adenocarcinoma and revealed that \( p53 \) was positive in 46% patients (in our study, 41.7% of patients were \( p53 \) positive), and similar to the present study, there was no significant relationship between the expression of this marker and grade of tumor, type of tumor (based on the Lauren classification), and lymphatic metastasis; however, a significant relationship existed only between the expression of \( p53 \) and the survival rate of patients (with odds ratio = 1.89, 95% confidence interval 1.33-2.69). For the death and five-year survival, it was 3% in patients with \( p53 \) expression compared to 16% in patients without it. Their findings were similar to the results of the present research.

The expression of HER-2/neu has been proved to occur in stomach adenocarcinoma and the gastroesophageal junction. In spite of the high probability of association, the expression of this marker is related to poorer prognosis, resistance to conventional chemotherapy in this malignancy, and other carcinomas. Recently, researchers found that when this marker is expressed, anti-HER2 antibody trastuzumab treatments can be used, and thus its detection has a high therapeutic value (Hechtman and Polydorides, 2012). Retrospective investigation of 120 patients with gastric cancer following surgery by Una Cidon (2012) indicated that the expression of HER-2/neu gene was observed in 7.5% of patients and its positivity was significantly correlated with female gender, intestinal form, and more advanced stages of this cancer. According to the study by Park et al., (2006) on 180 patients with gastric cancer, 15.9% of patients, in which HER-2/neu had been expressed, highly experienced the intestinal type of tumor, and these patients had a shorter five-year survival compared to those without it. However, this gene expression in the present study was higher (33.3%) and its expression, as with this study, was significantly related to the intestinal form of adenocarcinoma. On the other hand, in spite of the lower rate of survival in positive HER-2/neu patients (20.15 months versus 26.65 months), this difference was not significant. In several other studies, the expression of HER-2/neu was associated with the intestinal type of adenocarcinoma and poorer prognosis (Liu et al., 2012; Hsu et al., 2011; Wang and Zhang 2017). Based on the previous studies, membrane immunoreactivity is observed only in the intestinal type (Lemoine et al., 1991; Falck and Gullick 1989). However, the reasons for the selective expression of HER-2/neu in

Table 3. Relationship between Demographic Variables as Well as Tumor Features and the Extent of Expression of Ki67 and HER-2/neu

| Variables          | Group     | Ki67 | P-Value | CD44 | P-Value |
|--------------------|-----------|------|---------|------|---------|
| Tumor type         | Intestinal| 33.36| 0.288   | 21.5 | 0.934   |
|                    | Diffuse   | 42.00| 0.94    | 32   | 41.40   |
|                    | Mixed     | 53.33| 47.26   | 26.67| 37.86   |
|                    | Mucinous  | 14.29| 25.07   | 30   | 47.96   |
| Gross Appearance   | Ulcerative| 37.14| 0.654   | 28.71| 0.447   |
|                    | Polypoid  | 16.67| 20.82   | 8.33 | 10.41   |
|                    | Infiltrative| 30.68| 34.17   | 20   | 33.52   |
| Tumor location     | Corpus    | 30.00| 33.72   | 0.704| 21.64   |
|                    | Fundus    | 13.33| 23.9    | 6.67 | 11.55   |
|                    | Antrum    | 38.5 | 32.97   | 35   | 37.17   |
|                    | Cardia    | 37.08| 35.70   | 24.17| 32.88   |
|                    | Prepyloric| 34.00| 47.75   | 32   | 46.04   |
| Tumor Grade        | Grade 1   | 26.67| 28.05   | 0.389| 22.5    |
|                    | Grade 2   | 40.63| 33.11   | 26.25| 28.41   |
|                    | Grade 3   | 29.67| 35.96   | 23.5 | 36.42   |
| Tumor Stage        | T1        | 0.00 | 0.732   | 0    | 0.64    |
|                    | T2        | 38.00| 39.67   | 34   | 42.22   |
|                    | T3        | 35.00| 34.72   | 26.5 | 31.79   |
|                    | T4        | 32.59| 32.8    | 20.69| 29.15   |
| Lymph node involvement | N0 | 31.54| 39.34   | 0.786| 24.62   |
|                    | N1        | 31.43| 30.35   | 24.64| 25.61   |
|                    | N2        | 41.67| 38.25   | 24.67| 29.24   |
|                    | N3        | 30.56| 30.96   | 24.17| 37.43   |
| Lymphovascular involvement | Lymph+ Vasc+ | 38.39| 32.06   | 0.55 | 28.04   |
|                    | Lymph- Vasc-| 24.71| 33.75   | 21.18| 38.55   |
|                    | Lymph+ Vasc-| 32.73| 36.08   | 22.27| 24.04   |
|                    | Lymph- Vasc+| 42.50| 49.24   | 20   | 32.16   |

Asian Pacific Journal of Cancer Prevention, Vol 21 1611
the intestinal type of carcinoma seems to be complex. This oncogene is associated with the intestinal phenotype of carcinoma. Nevertheless, since not all intestinal type tumors show the expression of HER-2/neu, it cannot be the only factor involved in the development of such a type of adenocarcinoma. In addition, it seems unlikely that all intestinal tumors be developed by an external cause, and this may justify the different prevalence of the expression of HER-2/neu across different cases. Finally, investigation of 1036 patients by Hsu et al., (2011) and based on the

Figure 2. Evaluation of Age, Gender, Survival Rate and Tumor Size with Respect to Expression Levels of Ki-67 and CD44

Figure 3. HER2/neu Expression in Gastric Adenocarcinoma. A, score 0; B, score 1+; C, score 2+ and D: score 3+.
The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer

Based on the research, Ki-67 antigen plays a significant role in regulating cellular proliferation and has prognostic value in many types of cancer (Huang et al., 2016). In the present study, Ki-67, as an independent factor, had no diagnostic value in predicting the biological behavior of stomach adenocarcinoma and rate of patients’ survival. Huang et al., (2016) study demonstrated that high Ki-67 expression (immunohistochemistry score > or = 3+) was a significant prognostic factor for relapse, remote metastasis, and overall survival of patients. The study conducted by Stahl et al., (2017) also showed that the expression of this biomarker was associated with shorter survival. The reason for the different result may be because of differences in immunohistochemical staining and scoring systems. Finally, Shafigh et al., (2007) study on 58 patients revealed that investigation of p53 and Ki-67 markers alone had no diagnostic value in predicting the biological behavior of gastric cancer.

According to the studies, CD44 is one of the most common markers of cancer stem cells (CSCs) in gastric cancer, which has the potential for regeneration, initiation of tumor progression, and possibly development of metastasis. In the present study, no significant relationship was found between the extent of expression of this biomarker and demographic characteristics or histological features of patients. Moreover, (Wakamatsu et al., 2012; Lu et al., 2016; Ibrahim et al., 2018) concluded that the expression of CD44 is associated with a poorer prognosis and lower survival of patients (Wakamatsu et al., 2012; Lu et al., 2016; Ibrahim et al., 2018). The result difference may be due to methodology and/or sample size. In addition, Nosrati et al., (2014) investigated 95 samples of the primary adenocarcinoma of the stomach and observed a relationship between CD44 and the intestinal type of tumor, tumor size (4-8 cm), depth of invasion, and moderate differentiation.

Of course, some studies investigated these four biomarkers concurrently. In a study conducted by Sanat et al., (2017) on 100 patients, it was found that only p53 and CD44 were associated with the lifespan of patients, and no relationship was found between the expression of Ki-67 or HER-2/neu and the extent of survival of patients.

In conclusion, according to the results, p53 and CD44 markers had no diagnostic value in predicting the biological behavior of the gastric cancer. Moreover, incidence of mutation in p53 gene was related with the lower rate of survival, and the expression of HER-2/neu was associated with higher probability of developing the intestinal type of stomach adenocarcinoma and ulcerative gross feature. Therefore, it was suggested that future studies address a larger sample size in this regard, matching the sample as to gender, types ratio and grades. In addition, future studies can deal with the comparison of other markers such as other CSCs, including CD133, examination of the relapse of patients following surgery, and the relationship between markers and their effect on the relapse of adenocarcinoma.

References

Al Moundhri MS, Nirmala V, AL-Hadabi I, et al (2005). Asian Pacific Journal of Cancer Prevention, Vol 21 1613
The prognostic significance of P53 and Ki-67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study of Arab patients. *J Surg Oncol*, **4**, 243-52.

Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. *Cancer Res*, **24**, 6754-40.

DeVita TL, Theodore S, Rosenberg SA (2008). Devita, hellman and rosenberg cancer. *Principles*, **8**, 989-92.

Falck VG, Gullick WJ (1989). C-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochchemical study. The Journal of pathology, **2**, 107-11.

Hechtman JF, Polydorides AD (2012). HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. *Arch Pathol Lab Med*, **6**, 691-7.

Hsu JT, Chen TC, Tseng JH, et al (2011). Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. *Oncologist*, **12**, 1706-13.

Huang G, Chen S, Wang D, et al (2016). High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. *Clin Lab*, **2**, 141-53.

Ibrahim HM, AbdElbary AM, Mohamed SY, et al (2018). Prognostic value of cyclin D1 and CD44 expression in Gastric Adenocarcinoma. *J Gastrointestinal Cancer*, **2**, 1-10.

Jovanović I, Todorović V, Milosavljević T, et al (2005). Expression of p53 protein in Barrett’s adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. *Vojnosanit Pregl*, **12**, 879-85.

Joy保罗BV, Hopwood DN, Newman EL, et al (1994). The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. *Br J Cancer*, **5**, 943.

Kunz PL, Gutbens M, Fisher GA, et al (2012). Long-term survivors of gastric cancer: a california population-based study. *J Clin Oncol*, **28**, 3507-15.

Lemoine NR, Jain S, Silvestre F, et al (1991). Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. *Br J Cancer*, **1**, 79.

Lindboe CF, Von Der Ohe G, Torp SH (2003). Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. *Apmis*, **5**, 567-70.

Liu XP, Tsubumi K, Tsubimi M, et al (2001). Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. *Pathol Int*, **6**, 440-4.

Liu W, Zhong S, Chen J (2012). HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. *Journal of clinical gastroenterology*, **4**, 31-7.

Lu L, Wu M, Sun L, et al (2001). Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved. *Medicine*, **42**, 95.

Milner J, Watson JV (1990). Addition of fresh medium induces proliferation index in neoplasms using different Ki-67 expression patterns. *Oncogene*, **5**, 1683 – 90.

Mohagheghi M, Jarahi AM, Torbaghan SS (1998). Annual Report of Tehran University of Medical Sciences District Cancer Registry 1997.

Mohagheghi M. (2004). Annual Report of Tehran Cancer Registry 1999. The Cancer Institute Publication.

Morales TG (1997). Adenocarcinoma of the gastric cardia. *Digestive diseases*, **15**, 346-56.

Nosrat A, Naghshvar F, Khanari S (2014). Cancer stem cell markers CD44, CD133 in primary gastric adenocarcinoma. *International journal of molecular and cellular medicine*, **4**, 279.

Parsonnet J, Friedman GD, Vandersteen DP, et al (1991). Helicobacter pylori infection and the risk of gastric carcinoma. *New Engl J Med*, **16**, 1127-31.

Park DI, Yun JW, Park JH, et al (2006). HER-2/neu amplification is an independent prognostic factor in gastric cancer. *Dig Dis Sci*, **8**, 1371-9. 21.

Pinto-de-Sousa J, Silva F, David L, et al (2004). Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. *Histopathology*, **4**, 323-31.

Sanaz Z, Halimi M, Ghojmezadeh M, et al (2013). Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran. *Int J Hematol Oncol Stem Cell Res*, **3**, 15-2.

Shun CT, Wu MS, Lin JT, et al (1997). Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. *Hepatogastroenterology*, **14**, 604-9.

Smith MG, Hold GL, Tahara E, et al (2006). EM.Cellular and molecular aspects of gastric cancer. *World J Gastroenterol*, **12**, 2979-90.

Shafigh E, Abdolazimi Y, Shaifaie Sh (2007). Expression of biomarkers Ki-67, p27kip1,p53 in gastric cancer andtheir association with histopathologic indicators of gastrectomy samples of patients reffered to Shahid Beheshti hospital Babol Iran in2000-2006. *Univ Med Sci Babol*, **4**, 7.

Staib I, Robeles AI, Varticovski I (2005).The tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. *Cancer Res*, **22**, 10255-64.

Stahl D, Braun M, Gentles AJ, et al (2017). Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma. *Oncotarget*, **44**, 76329.

Trédaniel J, Boffetta P, Buiatti E, et al (1997). Tobacco smoking and gastric cancer: review and meta-analysis. *Int J Cancer*, **4**, 565-73.

Una Cidon E (2012). HER2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain. *J Clin Oncol*, **4**, 60-6.

Wang HB, Liao XF, Zhang J (2017). Clinicopathological factors associated with HER2-positive gastric cancer: a meta-analysis. *Medicine*, **44**, 96.

Wakamatsu Y, Sakamoto N, Oo HZ, et al (2012). Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. *Pathol Int*, **2**, 112-9.Ur, omnihit plabo. Ut erorest volupta